STOCK TITAN

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.

Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.

Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.

Rhea-AI Summary
Novavax, Inc. (NVAX) Receives FDA and European Commission Approval for Updated COVID-19 Vaccine, Announces Financial Results and Operational Highlights for Q3 2023. Key points include the launch of a non-mRNA vaccine, WHO recommendation for the Matrix-M malaria vaccine, and anticipated Phase 3 COVID-19-Influenza Combination vaccine trial. The company also plans to initiate a cost reduction program to align with future market opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Novavax, Inc. will report its Q3 2023 financial results and operational highlights on November 9, 2023, at 8:30 a.m. EST. Conference call details and replay information are provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences earnings
-
Rhea-AI Summary
Novavax's updated COVID-19 vaccine, Nuvaxovid™ XBB.1.5 dispersion for injection, has been granted approval by the European Commission for individuals aged 12 and older. The vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union. Novavax is working closely with EU member states to deliver the vaccine to those that have requested doses through the advance purchase agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
covid-19
Rhea-AI Summary
Novavax's Nuvaxovid™ XBB.1.5 COVID-19 vaccine has been recommended for approval in the European Union for individuals aged 12 and older. The vaccine has shown immune responses against multiple variants and is expected to receive final approval soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
covid-19
-
Rhea-AI Summary
Novavax receives full marketing authorization for its prototype COVID-19 vaccine in the UK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
covid-19
-
Rhea-AI Summary
Novavax's prototype COVID-19 vaccine receives full approval in Singapore for individuals aged 12 and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
covid-19
Rhea-AI Summary
Novavax announces agreements with major pharmacy retailers to provide its COVID-19 vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
covid-19
-
Rhea-AI Summary
Novavax to present study findings on COVID-19 vaccines at IDWeek and World Vaccine Congress Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
none
-
Rhea-AI Summary
Novavax partners with HealthyWomen and Nicole Ari Parker to launch Choose to Protect campaign to educate the public about COVID vaccination and vaccine options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
covid-19
Rhea-AI Summary
Novavax's COVID-19 vaccine receives Emergency Use Authorization and CDC recommendation, making it the only protein-based non-mRNA option in the U.S. Doses will be available in thousands of locations across the country. The vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants. Adverse reactions include headache, nausea, and fatigue. Seek medical attention for severe allergic reactions or symptoms of myocarditis or pericarditis. Pregnant or breastfeeding individuals should consult with healthcare providers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.18%
Tags
covid-19
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

965.07M
146.70M
8.8%
60.18%
24.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
GAITHERSBURG